Are NGL Fine Chem Ltd latest results good or bad?

NGL Fine Chem Ltd has reported notable financial results for the quarter ending March 2026, showcasing significant revenue growth alongside some challenges in profitability metrics. The company achieved its highest-ever quarterly revenue of ₹149.23 crores, reflecting a year-on-year increase of 57.13%, which indicates strong demand for its pharmaceutical intermediates and active pharmaceutical ingredients. This revenue growth is complemented by a remarkable year-on-year net profit surge of 2,398.15%, amounting to ₹13.49 crores, signifying a recovery from a previously depressed profit level. However, the data also reveals some operational challenges. Despite the impressive revenue and net profit figures, there was a sequential decline in net profit of 14.02% from the previous quarter, raising questions about the sustainability of profitability. The operating margin, excluding other income, contracted to 14.35% from 17.50% in the prior quarter, indicating rising cost pressures that may offset revenue gains. Similarly, the PAT margin decreased to 9.04% from 12.30% quarter-on-quarter, despite remaining significantly above the prior year's level. The company's return on equity (ROE) and return on capital employed (ROCE) metrics have also shown deterioration, with the latest ROE at 6.89% and ROCE at 7.15%, both significantly below their historical averages. This decline suggests that recent capital investments have not yet yielded the expected returns, which is a concern given the company's expansion efforts. In terms of valuation, NGL Fine Chem Ltd is trading at a premium compared to its peers, with a price-to-earnings ratio of 44 times trailing twelve-month earnings, which is substantially above the industry average. This high valuation reflects investor expectations for continued growth but also indicates a level of risk if the company fails to meet these expectations. Overall, while NGL Fine Chem Ltd has demonstrated strong revenue momentum and a significant recovery in net profit, the sequential decline in profitability metrics and the deterioration of return ratios warrant careful monitoring. The company has experienced an adjustment in its evaluation, reflecting the mixed signals from its financial performance.